ArticleNature communications2021
Induced organoids derived from patients with ulcerative colitis recapitulate colitic reactivity.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 106 citations in OpenAlex.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026Review
- Inflammatory Stromal Aging in Ulcerative Colitis and Colitis-Associated Cancer.bioRxiv : the preprint server for biology · 2026Article
- Restoration of the Mucosal Barrier by Lactobacillus gasseri HDS0266 and Enterococcus faecium HDS0288 in Dextran Sodium Sulfate and Clostridioides difficile-Induced Colitis Mice.Probiotics and antimicrobial proteins · 2026Article
- Dietary L-arginine supplementation exerts preventive effects on colitis through modulation of the gut microbiota.Frontiers in nutrition · 2026Article
- Biomechanical Phenotyping Reveals Unique Mechanobiological Signatures of Early-Onset Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Macrophage Immune-Competent Colon Assembloids for Functional Interrogation of Neuroinflammation-Induced Colonic Dysmotility.Gastro hep advances · 2026Article
- Immune and Immune-Integrated Organoids as NextGeneration Platforms for Disease Modeling.MedComm · 2025Review
- Nicheformer: a foundation model for single-cell and spatial omics.Nature methods · 2025Article
- Three-dimensional multicellular layer structure: an advanced in vitro model for studying inflammatory bowel diseases.Scientific reports · 2025Article
- Insights into Modeling Inflammatory Bowel Disease from Stem Cell Derived Intestinal Organoids.Stem cell reviews and reports · 2025Review
- Ion transport and epithelial barrier dysfunction in experimental models of ulcerative colitis.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- Coordinated differentiation of human intestinal organoids with functional enteric neurons and vasculature.Cell stem cell · 2025Article
- Leveraging Organ-on-Chip Models to Investigate Host-Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease.Advanced healthcare materials · 2025Review
- Extracellular Vesicles in Gut-Bone Axis: Novel Insights and Therapeutic Opportunities for Osteoporosis.Small science · 2025Review
- The application of explants, crypts, and organoids as models in intestinal barrier research.Tissue barriers · 2025Article
- Review
- Intestinal organ chips for disease modelling and personalized medicine.Nature reviews. Gastroenterology & hepatology · 2024Review
- Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review.Archives of toxicology · 2024Review
- A living organoid biobank of patients with Crohn's disease reveals molecular subtypes for personalized therapeutics.Cell reports. Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
The pathogenesis of ulcerative colitis (UC), a major type of inflammatory bowel disease, remains unknown. No model exists that adequately recapitulates the complexity of clinical UC. Here, we take advantage of induced pluripotent stem cells (iPSCs) to develop an induced human UC-derived organoid (iHUCO) model and compared it with the induced human normal organoid model (iHNO). Notably, iHUCOs recapitulated histological and functional features of primary colitic tissues, including the absence of acidic mucus secretion and aberrant adherens junctions in the epithelial barrier both in vitro and in vivo. We demonstrate that the CXCL8/CXCR1 axis was overexpressed in iHUCO but not in iHNO. As proof-of-principle, we show that inhibition of CXCL8 receptor by the small-molecule non-competitive inhibitor repertaxin attenuated the progression of UC phenotypes in vitro and in vivo. This patient-derived organoid model, containing both epithelial and stromal compartments, will generate new insights into the underlying pathogenesis of UC while offering opportunities to tailor interventions to the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.